A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

The gain was partially offset by an Otezla intangible asset impairment charge of $800 million recorded during the first quarter of 2025. Adjusted income for the period came in at $2.65 billion ...

Enbrel sales are likely to have declined due to declining prices. Otezla sales were soft in the past few quarters. Sales of Otezla and Enbrel are expected to have been lower in the first quarter ...

Scripps Research found that the FDA-approved drug apremilast may reduce both alcohol consumption and pain sensitivity, offering a promising dual therapy for alcohol use disorder. Scientists at Scripps ...

Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of ...

The results, published in JCI Insight on April 22, 2025, suggest that the drug apremilast—a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation—could be ...

The findings, published in JCI Insight, suggest that the drug apremilast might help lower alcohol consumption and ease pain sensitivity—two problems that often happen together in people with AUD.

Apremilast treatment for 1 year significantly reduced abdominal fat and maintained lean mass in patients with psoriatic arthritis (PsA), alongside notable improvements in disease activity. Those ...

Apremilast reduces co-occurring alcohol drinking and mechanical allodynia and regulates central amygdala GABAergic transmission. JCI Insight , 2025; 10 (8) DOI: 10.1172/jci.insight.189732 Cite ...

Get Instant Summarized Text (Gist) Apremilast, an FDA-approved phosphodiesterase-4 inhibitor, reduces both alcohol intake and pain sensitivity in rat models of alcohol use disorder. Its effects ...